Conclusion. Our analysis suggests that age and household exposure predict higher likelihood of protozoal infection in children with AGE. Classic epidemiologic exposures including travel and recreational water exposure were not predictive. These data could improve appropriate test selection. Future studies are still needed for external validation of this model. Background. Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is among the top 10 causes of death worldwide. Multidrug-resistant TB is increasing, with almost 480,000 new cases. According to drug resistance surveillance data, 3.9% of these are new cases and 21% previously treated TB cases. The aim of this study was to compare the results from the conventional drug susceptibility test (DST) and the sequencing method.
Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical
Methods. During 2017, we prospectively collected consecutive clinical strains of MRSA recovered from the blood or other sterile sites in ten tertiary-care hospitals in Santiago, Chile. One isolate per patient was obtained. Identification was confirmed by MALDI-TOF and susceptibility testing of all isolates was performed at a central lab. CPT susceptibility was evaluated by BMD and KB following CLSI 2017 directions. Etest was performed as per manufacturer's instructions. Categorical agreement (CA), essential agreement (EA) and very major errors (VME) were evaluated. Susceptibilities were analyzed using CLSI established breakpoints Results. Forty unique MRSA isolates were tested. Using BMD, the MIC 50 /MIC 90 was 2/4 μg/dL, respectively. Moreover, only 18 (45%) isolates were CPT susceptible. Out of the remaining 22 MRSA strains, 8 (20%) were intermediate and 14 (35%) CPT-resistant (CPT-R). Using Etest, the MIC 50 /MIC 90 was 1/2 μg/dL, with 31 (78%) isolates being considered susceptible and the remaining catalogued as intermediate. CPT susceptibility using KB catalogued 38 (95%) isolates as susceptible and only 2 as intermediate. No CPT-R strains were found by Etest or KB. The CA was for Etest and KB, respectively; Etest's EA was 80%. Worryingly, out of 14 CPT-R isolates by BMD, 6 were deemed susceptible by Etest and 12 by KB, obtaining VME rates of 43 and 87%, respectively Conclusion. Performance of both Etest and KB to assess CPT susceptibility in MRSA isolates from Chile was poor, with a unacceptably high proportion of VME, and a CA lower than 50% for both techniques. Correlation of CPT susceptibility with the molecular epidemiology of the isolates is currently being performed Disclosures. All authors: No reported disclosures. Background. Plazomicin (PLZ) is a next-generation aminoglycoside with in vitro activity against MDR Enterobactericeae, including CRE. PLZ is currently under review at the FDA for the treatment of complicated urinary tract infections, including pyelonephritis, and bloodstream infections due to certain Enterobacteriaceae in patients who have limited or no alternative treatment option. This study was performed to evaluate the performance of a newly developed gradient strip, the plazomicin MIC Test Strip (MTS) from Liofilchem, Roseto degli Abruzzi, Italy compared with the broth microdilution method against relevant Enterobacteriaceae.
Comparison of
Methods. The study isolates included 125 Enterobacteriaceae (12 species as shown in the table), which were chosen to include a range of plazomicin MICs and isolates with known resistant mechanisms. Each isolate was tested for PLZ MIC by broth microdilution (BMD; LSI prepared frozen panels) and by PLZ MTS on 100 mm Mueller Hinton agar (MHA) plates (Becton Dickinson, Sparks, MD) and a subset of 20 strains was also tested on MHA plates from two additional manufacturers (Hardy, Santa Maria, CA and Remel, Lenexa, KA). Quality control (QC) strains (E. coli ATCC 25922 and P. aeruginosa ATCC 27853) were tested on each day of testing and results compared with CLSI expected ranges.
Results. As shown in the table, PLZ MTS and BMD results were within ± one doubling dilution (essential agreement) for 99.2% of all study isolates. The category agreement rate was 91.2% (based on proposed susceptible/intermediate/resistant breakpoints of ≤4/8/≥16 µg/mL) and there were no very major or major errors observed. The QC results were within CLSI published ranges. PLZ results for MTS tested on Remel and Hardy MHA for the subset of 20 isolates were similar to BD MHA results (equivalent or 1 dilution lower).
